SAB BIOTHERAPEUTICS, INC. (SABS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 49.27M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 16.68M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -71.82M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $49.27M | (m) | $16.68M | $-71.82M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $40.09M | (m) | $10.06M | $-58.18M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $34.35M | $0.00 | $5.21M | $-48.95M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $31.28M | (m) | $2.72M | $-43.19M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $30.14M | (m) | $2.96M | $-41.82M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $29.76M | (m) | $2.94M | $-42.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $30.25M | $1.32M | $2.94M | $-42.91M | (m) | 2287.62% | 222.46% | (m) | (m) |
| 2024-09-30 | $26.90M | $1.51M | $2.80M | $-51.78M | (m) | 1778.08% | 185.40% | (m) | (m) |
| 2024-06-30 | $23.09M | $2.78M | $2.40M | $-45.79M | $317.07K | 830.42% | 86.15% | -144.41× | Reported |
| 2024-03-31 | $20.13M | $2.60M | $2.44M | $-42.06M | $299.27K | 773.32% | 93.70% | -140.56× | Reported |
| 2023-12-31 | $16.52M | $2.24M | $2.42M | $-38.08M | $315.28K | 737.61% | 108.25% | -120.77× | Reported |
| 2023-09-30 | $19.36M | $4.09M | $2.52M | $-27.06M | $325.10K | 472.68% | 61.43% | -83.24× | Reported |
| 2023-06-30 | $22.69M | $6.42M | $2.45M | $-29.55M | $326.03K | 353.56% | 38.25% | -90.62× | Reported |
| 2023-03-31 | $27.65M | $12.68M | $2.38M | $-29.61M | $321.95K | 218.02% | 18.76% | -91.98× | Reported |
| 2022-12-31 | $36.44M | $23.90M | $2.67M | $-28.92M | $301.58K | 152.44% | 11.19% | -95.89× | Reported |
| 2022-09-30 | $39.95M | $32.80M | $2.70M | $-28.40M | $280.16K | 121.79% | 8.22% | -101.38× | Reported |
| 2022-06-30 | $47.67M | $43.89M | $3.00M | $-24.58M | $288.09K | 108.60% | 6.83% | -85.34× | Reported |
| 2022-03-31 | $57.73M | $55.75M | $2.86M | $-20.91M | $291.29K | 103.54% | 5.14% | -71.80× | Reported |
| 2021-12-31 | $57.18M | $60.88M | $2.31M | $-13.39M | $294.46K | 93.93% | 3.80% | -45.48× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $27.91M | $55.24M | $1.30M | $20.56M | $469.15K | 50.52% | 2.35% | 43.82× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |